Supernus Pharmaceuticals, Inc. (LON: 0LB2)

Market Cap	1.71B
Revenue (ttm)	486.44M
Net Income (ttm)	44.55M
Shares Out	n/a
EPS (ttm)	0.80
PE Ratio	38.41
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	180
Open	38.43
Previous Close	37.61
Day's Range	37.77 - 38.43
52-Week Range	22.54 - 38.65
Beta	n/a
RSI	60.51
Earnings Date	Feb 27, 2025

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2005
• Employees: 652
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LB2

Financial Performance

In 2023, Supernus Pharmaceuticals's revenue was $607.52 million, a decrease of -8.95% compared to the previous year's $667.24 million. Earnings were $1.32 million, a decrease of -97.83%.

Financial numbers in USD